The Antibacterial Effects of an Antimicrobial Peptide Human β-Defensin 3 Fused with Carbohydrate-Binding Domain on Pseudomonas aeruginosa PA14

详细信息    查看全文

• 作者：Ping Lin ; Yong Li ; Ke Dong ; Qingtian Li
• 刊名：Current Microbiology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：71
• 期：2
• 页码：170-176
• 全文大小：392 KB
• 参考文献：1.Bodey GP, Bolivar R, Fainstein V, Jadeja L (1983) Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 5:279-13PubMed View Article
  2.Rossolini GM, Mantengoli E (2005) Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11(Suppl 4):17-2PubMed View Article
  3.Obritsch MD, Fish DN, MacLaren R, Jung R (2005) Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-364PubMed View Article
  4.Fischetti VA (2001) Phage antibacterials make a comeback. Nat Biotechnol 19:734-35PubMed View Article
  5.Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ (2008) Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 104:1-3PubMed
  6.Lee JK, Chang SW, Perinpanayagam H, Lim SM, Park YJ, Han SH, Baek SH, Zhu Q, Bae KS, Kum KY (2013) Antibacterial efficacy of a human beta-defensin-3 peptide on multispecies biofilms. J Endod 39:1625-629PubMed View Article
  7.Li Q, Huang J, Guo H, Guo X, Zhu Y, Dong K (2012) Bactericidal activity against meticillin-resistant Staphylococcus aureus of a novel eukaryotic therapeutic recombinant antimicrobial peptide. Int J Antimicrob Agents 39:496-99PubMed View Article
  8.Samy RP, Thwin MM, Chow VT, Bow H, Gopalakrishnakone P (2011) Evaluation of antibacterial activity of proteins and peptides using a specific animal model for wound healing. Methods Mol Biol 716:245-65PubMed View Article
  9.Miki T, Holst O, Hardt WD (2012) The bactericidal activity of the C-type lectin RegIIIbeta against Gram-negative bacteria involves binding to lipid A. J Biol Chem 287:34844-4855PubMed Central PubMed View Article
  10.Jones C, Hachani A, Manoli E, Filloux A (2014) An rhs gene linked to the second type VI secretion cluster is a feature of the Pseudomonas aeruginosa strain PA14. J Bacteriol 196:800-10PubMed Central PubMed View Article
  11.Schaber JA, Carty NL, McDonald NA, Graham ED, Cheluvappa R, Griswold JA, Hamood AN (2004) Analysis of quorum sensing-deficient clinical isolates of Pseudomonas aeruginosa. J Med Microbiol 53:841-53PubMed View Article
  12.Darzins A (1993) The pilG gene product, required for Pseudomonas aeruginosa pilus production and twitching motility, is homologous to the enteric, single-domain response regulator CheY. J Bacteriol 175:5934-944PubMed Central PubMed
  13.Glessner A, Smith RS, Iglewski BH, Robinson JB (1999) Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of twitching motility. J Bacteriol 181:1623-629PubMed Central PubMed
  14.Li Q, Zhou Y, Dong K, Guo X (2010) Potential therapeutic efficacy of a bactericidal-immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus skin infection. Appl Microbiol Biotechnol 86:305-09PubMed View Article
  15.Zhu C, Tan H, Cheng T, Shen H, Shao J, Guo Y, Shi S, Zhang X (2013) Human beta-defensin 3 inhibits antibiotic-resistant Staphylococcus biofilm formation. J Surg Res 183:204-13PubMed View Article
  16.Bardoel BW, van Kessel KP, van Strijp JA, Milder FJ (2012) Inhibition of Pseudomonas aeruginosa virulence: characterization of the AprA-AprI interface and species selectivity. J Mol Biol 415:573-83PubMed View Article
  17.Medina G, Juarez K, Valderrama B, Soberon-Chavez G (2003) Mechanism of Pseudomonas aeruginosa RhlR transcriptional regulation of the rhlAB promoter. J Bacteriol 185:5976-983PubMed Central PubMed View Article
  18.O’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL (2013) A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc Natl Acad Sci USA 110:17981-7986PubMed Central PubMed View Article
  19.Li P, Poon YF, Li W, Zhu HY, Yeap SH, Cao Y, Qi X, Zhou C, Lamrani M, Beuerman RW, Kang ET, Mu Y, Li CM, Chang MW, Leong SS, Chan-Park MB (2011) A polycationic antimicrobial and biocompatible hydrogel with microbe membrane suctioning ability. Nat Mater 10:149-56PubMed View Article
  20.Ochsner UA, Vasil ML, Alsabbagh E, Parvatiyar K, Hassett DJ (2000) Role of the Pseudomonas aeruginosa oxyR-recG operon in oxidative stress defense and DNA repair: oxyR-dependent regulation of katB-ankB, ahpB, and ahpC-ahpF. J Bacteriol 182:4533-544PubMed Central PubMed View Article
  21.Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis 52:1038-045PubMed View Article
  22.Hengzhuang W, Hoiby N, Ciofu O (2014) Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo. Methods Mol Biol 1147:239-54PubMed View Article
  23.Kumar L, Chhibber S, Harjai K (2013) Zingerone inhibit biofilm formation and improve antibiofilm efficacy of ciprofloxacin against Pseudomonas aeruginosa PAO1. Fitoterapia 90:7
• 作者单位：Ping Lin (1)
  Yong Li (2)
  Ke Dong (3)
  Qingtian Li (1) (3)
  
  1. Department of Medical Laboratory, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China
  2. Department of Respiratory Medicine, Luwan Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
  3. Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, B06, Building 1, 280 South Chongqing Road, Shanghai, 200025, China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Microbiology
  Biotechnology
  
• 出版者：Springer New York
• ISSN：1432-0991

文摘

Pseudomonas aeruginosa is one of the most opportunistic bacterial pathogens in human communities. Being a potential antibacterial agent, antimicrobial peptide human β-defensin 3-carbohydrate-binding domain (hBD3-CBD) was evaluated in this study by in vitro bactericidal test, special gene expressions, hBD3-CBD effects on biofilm formation assays, swimming, twitching, and swarming activities of P. aeruginosa PA14, and hBD3-CBD effects on the antibiotic 50?% minimal inhibitory concentration (MIC50) and 90?% minimal inhibitory concentration (MIC90) against clinical P. aeruginosa isolates. The MIC against P. aeruginosa PA14 was 32?μg/ml; hBD3-CBD showed significant bactericidal activities when the concentration reached 8?μg/ml, and when the concentration reached 2 μg/ml, hBD3-CBD successfully repressed the biofilm productions in P. aeruginosa PA14. hBD3-CBD could inhibit the in vitro swimming, twitching, and swarming activities of P. aeruginosa PA14. When 5?μg/ml hBD3-CBD was combined with antibiotics, it decreased the MIC50 and MIC90 of tetracycline, rifampicin, and streptomycin against clinical P. aeruginosa isolates. As new antibacterial agents, hBD3-CBD and other AMPs might be used together with antibiotics to deal with infections in the future, especially the skin and soft tissue infections of drug-resistant P. aeruginosa.